



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/588,792	10/26/2006	Hiroyuki Kamiya	2006_1315A	9531
513 7590 02/16/2011 WENDEROTH, LIND & PONACK, L.L.P. 1030 15th Street, N.W., Suite 400 East Washington, DC 20005-1503				
EXAMINER				
PANDE, SUCHIRA				
ART UNIT		PAPER NUMBER		
1637				
NOTIFICATION DATE		DELIVERY MODE		
02/16/2011		ELECTRONIC		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

ddalecki@wenderoth.com
coa@wenderoth.com

Office Action Summary

Application No.

10/588,792

Applicant(s)

KAMIYA ET AL.

Examiner

SUCHIRA PANDE

Art Unit

1637

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 26 January 2011.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 12, 13 and 15-23 is/are pending in the application.
- 4a) Of the above claim(s) 17-22 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 12, 13, 15, 16 and 23 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-940)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB-08)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

Claim Status

1. Amendment filed on 1/26/2011 is acknowledged. Base claim 12 has been amended. Claims 1-11 and 14 are cancelled. Claims 17-22 are withdrawn. Claims 12-13, 15-16 and 23 are active and will be examined in this action.

Response to Arguments

Re 103 rejection of claims 12-13, 15-16 and 23 over Zarling et al. in view of

Moriya

2. Applicant's arguments filed 1/26/2011 have been fully considered but they are not persuasive. Applicant has amended claim 12 to recite that the single stranded DNA fragment is homologous with a sense strand of the target DNA sequence.

Zarling et al. teaches an in vitro base conversion method of a DNA sequence, which is a method of converting one or more bases in a target DNA sequence in a cell. Zarling et al. do not teach preparing a single-stranded DNA fragment by cleavage from a single- stranded circular DNA. Examiner has used Moriya to teach preparing a single-stranded DNA fragment by cleavage from a single- stranded circular DNA. Moriya teaches use of shuttle phagemid vectors for production of single stranded DNA. One of ordinary skill in the art knows that shuttle phagemid vectors have architecture that allows one to express the desired (+sense strand) or (- antisense strand) strand. So 100 % of the DNA produced as single stranded DNA is the desired sense or antisense strand. If one desires to have 100% population containing only either the + or the - strand, then

Art Unit: 1637

the target gene of appropriate fragment size can be cloned in the multiple cloning site of the chosen phagemid vector. These phagemid clones will produce single stranded circular DNA containing the desired + or – strands.

Hence one of ordinary skill in the art can use appropriate single stranded DNA containing the desired sequence that one wishes to introduce into a cell such that the single stranded DNA fragment is homologous with a sense strand of the target DNA sequence. Thus cited art teaches all the aspects of the amended claim and hence obviousness 103 rejection is being maintained.

Applicant points to conversion efficiency and states that this superior efficiency is not taught or suggested by cited prior art

. Examiner would like to point out that conversion efficiency depends on several factors such as cells being used for conversion, length of the fragment and other conditions used for transformation. The instant claims do not recite any particular conditions, not do they recite conversion efficiency, hence arguments regarding conversion efficiency are not commensurate with the scope of the claimed invention.

Claim Rejections - 35 USC § 103

3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

4. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

5. Claims 12-13 and 15-16 and 23 are rejected under 35 U.S.C. 103(a) as being unpatentable over Zarling et al. (US PG PUB 2004/0019916 A1 with priority back to 1997—previously cited) in view of Moriya (1993) Proc. Natl. Acad. Sci. USA vol. 90 pp1122-1126 (previously cited).

Regarding claim 12, Zarling et al. teaches an *in vitro* base conversion method of a DNA sequence, which is a method of converting one or more bases in a target DNA sequence in a cell (CFTR gene is taught as target gene for base conversion. See page 16 par. 0132 where human cell line ECFTE29o- containing Δ F508 mutation of CFTR gene is taught. This cell line is used to replace Δ F508 allele of CFTR with wild type CFTR DNA by homologous recombination—in vitro base conversion—of instant claim),

consisting of preparing a single-stranded DNA fragment having 300 to 3,000 bases (see page 19 par. 0150, where wild type CFTR 491 mer ssDNA

Art Unit: 1637

fragment is taught. By teaching fragment of 491 mer Zarling et al. teach a fragment having 300 to 3,000 bases)

and introducing said single-stranded DNA fragment into a cell (see page 16 par. 0134 where 491 bp fragment is denatured at 950C and coated with rec A protein to keep it in single stranded form, which is then used for transfections, thus teaching introducing said single-stranded DNA fragment into a cell),

wherein said single-stranded DNA fragment is homologous with a sense strand of the target DNA sequence, and contains the base(s) to be converted (see page 16 par. 0132 where selection of 491 bp region of the CFTR gene spanning exon 11 and containing 3' and 5' flanking intron sequences from published data is described. This 491 bp region from wild type CFTR gene contains both the strands. See par. 0133 and 0134 where 491 bp PCR fragment is denatured to produce two single stranded 491 base sequences. Each of the denatured strands are coated with recA protein and introduced into cells. So 50% of denatured coated single-stranded DNA fragment is homologous with a sense strand of the target CFTR DNA sequence, and contains the base(s) to be converted).

Regarding claim 15, Zarling et al. teaches wherein the target DNA sequence in the cell is a DNA sequence causing a disease due to the one or more bases (see page 16 par. 0131 where target DNA associated with CFTR gene is taught. CFTR is associated with human disease cystic fibrosis. See page 19 par. 0150 where CFTR genomic DNA containing a 3bp Δ F508 deletion is taught as the target that causes disease).

Art Unit: 1637

Regarding claim 16, Zarling et al. teaches wherein one or more bases in a target DNA sequence in a cell of an organism are converted (see page 18 par. 0147 where homologous recombination between the targeting polynucleotide comprising WT CFTR and $\Delta F508$ mutant cellular DNA allelic target in transfected-CF-cells is taught).

Regarding claim 23, Zarling et al. teaches wherein the target gene is genomic or mitochondrial DNA (CFTR gene is located in chromosome 7 hence teaching target gene is genomic DNA).

Regarding claim 12, Zarling et al. do not teach preparing a single-stranded DNA fragment by cleavage from a single- stranded circular DNA. Method used by Zarling et al. for preparing single stranded DNA is denaturation of the PCR fragment.

Regarding claim 12, Moriya et al. teach preparing a single-stranded DNA (see page 1123 line 1 where ssPMS2 DNA is taught. Also see page 1122 last par. where isolation of ssPMS2 is taught. Thus by teaching isolation of ssPMS2 DNA, Moriya teaches preparing a single-stranded DNA)

fragment by cleavage from a single- stranded circular DNA, (see page 1122 Materials and method section where presence of hairpin structure containing *EcoRV* and *Sall* in pMS2 is taught. This hairpin structure containing *EcoRV* and *Sall* is used to linearize ssPMS2. Thus Moriya teaches cleavage of (ssPMS2) a single-stranded circular DNA using restriction enzymes to prepare a fragment).

Regarding claim 13, Moriya teaches wherein the single-stranded circular DNA is a phagemid DNA (see above as described in claim 12).

It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to practice the method of Moriya et al. in the method of Zarling et al. The motivation to do so is provided to one of ordinary skill in the art by knowledge of art itself.

One of ordinary skill in the art knows that when PCR amplified fragment is used as a source of single stranded DNA then denaturation of the fragment yields equimolar quantities of + (+ also referred as sense strand) and - (- also referred as antisense strand) strand (50% + and 50% -). Hence the resulting DNA is a mixture of the two strands.

One of ordinary skill in the art knows that shuttle phagemid vectors have architecture that allows one to express the desired (+sense strand) or (-antisense strand) strand. So 100 % of the DNA produced as single stranded DNA is the desired sense or antisense strand. The target gene of appropriate fragment size can be cloned in the multiple cloning site of the chosen appropriate phagemid vector. These phagemid clones can be used to produce single stranded circular DNA of desired sense. Moriya teaches how desired fragment can be cleaved from this single stranded DNA. In this case 100% of the single-stranded DNA fragment is homologous with a sense strand of the target DNA sequence, and contains the base(s) to be converted.

One of ordinary skill in the art also has a reasonable expectation that by practicing the method of Moriya in the method of Zarling et al. i.e. by cloning

Art Unit: 1637

desired target in the phagemid taught by Moriya, one of ordinary skill in the art would be able to prepare desired (DNA fragment that is homologous with a sense strand of the target strand) single stranded DNA fragment. This single stranded DNA fragment obtained can be transfected into desired host cells to successfully perform targeted homologous recombination.

Conclusion

6. All claims under consideration 12-13, 15-16 and 23 are rejected over prior art.
7. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Art Unit: 1637

Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUCHIRA PANDE whose telephone number is (571)272-9052. The examiner can normally be reached on 6:30 am -3:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 571-272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Suchira Pande
Examiner
Art Unit 1637

/Teresa E Strzelecka/
Primary Examiner, Art Unit 1637
February 11, 2011